Restaging After Neo-Adjuvant Chemoradiotherapy for N2 Non-Small Cell Lung Cancer

Thoracic Surgery Clinics

Volumn 18, Issue 4, 2008, Pages 417-421

  Cerfolio, Robert J ^a   Bryant, Ayesha S ^a  

^a Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; PEROPERATIVE CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; THORACOSCOPY; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEDIASTINUM; NEOADJUVANT THERAPY; NEOPLASM STAGING;

EID: 53849094792     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2008.08.002     Document Type: Review

References (25)

1. National Cancer Institute. Surveillance, epidemiology and end results (SEER) public use data 1973-2002. Available at:. http://seer.cancer.gov/publicdata Accessed June 15, 2005
2. Cerfolio R.J., and Bryant A.S. Survival of patients with unsuspected N2 (stage IIIA) non small-cell lung cancer. Ann Thorac Surg 86 (2008) 362-366
3. Cerfolio R.J., Maniscalco L.M., and Bryant A.S. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives?. Ann Thorac Surg 86 (2008) 912-920
4. Rosell R., Gomez-Codina J., Camps C., et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26 (1999) 7-14
5. Roth J., Fossella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
6. Detterbeck F., and Socinski M. Induction chemotherapy and surgery for I-III A, B non-small cell lung cancer. In: Detterbeck F., Socinski M., Rivera M., et al. (Eds). Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician (2001), WB Saunders Co, Philadelphia 267-282
7. Bueno R., Richards W., Swanson S., et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 70 (2000) 1826-1831
8. Voltolini L., Luzzi L., Ghiribelli C., et al. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg 20 (2001) 1106-1112
9. Komaki R., Cox J.D., Hartz A.J., et al. Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol 8 (1985) 362-370
10. Cerfolio R.J., Bryant A.S., and Eloubeidi M.A. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest 130 (2006) 1791-1795
11. Smith M.A., Battafarno R.J., Meyers R.F., et al. Prevalence of benign disease in patients undergoing resection for suspected lung cancer. Ann Thorac Surg 81 (2006) 1824-1828
12. Cerfolio R.J., Bryant A.S., Spencer S.A., et al. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 80 (2005) 1224-1230
13. Cerfolio R.J., Bryant A.S., and Yamamuro M. Intercostal muscle flap to buttress the bronchus at risk and the thoracic esophageal-gastric anastamosis. Ann Thorac Surg 80 (2005) 1017-1020
14. Cerfolio R.J., and Bryant A.S. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?. Ann Thorac Surg 84 (2007) 1092-1097
15. Cerfolio R.J., Bryant A.S., and Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 131 (2006) 1229-1235
16. Mateu-Navarro M., Rami-Porta R., Bastus-Piulats R., et al. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 70 (2000) 391-395
17. Pitz C., Mass K., Swieten H., et al. Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer. Ann Thorac Surg 74 (2002) 164-169
18. Van Schil P., Schoot van der J., Poniewierski J., et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer 37 (2002) 281-285
19. Annema J.T., Veselic M., Versteegh M.I., et al. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer 42 (2003) 311-318
20. Cerfolio R.J., Ojha B., Mukherjee S., et al. Positron emission tomography scanning with 2-fluoro-2-deoxyglucose as a predictor of response for non-small cell cancer. J Thorac Cardiovasc Surg 125 (2003) 938-944
21. Cerfolio R.J., Bryant A.S., Winokur T.S., et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 78 (2004) 1903-1909
22. Ryu J.S., Choi N.C., Fischman A.J., et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35 (2002) 179-187
23. Port J.L., Kent M.S., Korst R.J., et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 77 (2004) 254-259
24. Bryant A.S., Cerfolio R.J., Klemm K.M., et al. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 82 (2006) 417-422
25. Cerfolio R.J., and Bryant A.S. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph node to the primary tumor may be a universal predictor of nodal malignancy in patients with non-small cell lung cancer. Ann Thorac Surg 83 (2007) 1826-1830